Metsa Board Corp. Series B (0O7A)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 3.214 |
|---|---|
| 52-week range | 2.514 – 3.634 |
| Return, 1 month / 3 months | −5.5% / +12.2% |
| Return, 1 year / 3 years | +21.9% / −54.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 45 |
| Volatility (1 year) | 34.1% |
| Worst drawdown (1 year) | -20.1% |
| Average daily value traded | 0.10M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Metsä Board is a Finnish forest products company that makes fresh fibre paperboards and paper for packaging and printing uses. Its folding boxboard, white kraftliner and food service board go into consumer packaging, food and beverage packs, and graphic applications, while it also produces market pulp and sells to converters, brand owners and printers. The company is based in Finland and operates mills in the Nordic region, drawing on wood from sustainably managed forests.
Metsa Board Corp. Series B trades under the code 0O7A on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Metsa Board Corp. Series B (0O7A) trades on the London Exchange in UK. It last closed at EUR 3.214 on 20 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 1,053 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 21.9% and over the last three months it rose 12.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.7% | ||
| From 52-week high | -10.2% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 12.2% | ||
| 6-month return | 10.7% | ||
| 12-month return, skipping the last month | 28.9% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 34.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.1% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M EUR | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −4.6% |
|---|---|
| 1 month | −5.5% |
| 3 months | +12.2% |
| 6 months | +10.7% |
| 1 year | +21.9% |
| 3 years | −54.4% |
| 5 years | – |
Signals
| 50-day / 200-day average | 3.351 / 3.013 |
|---|---|
| Golden / death cross (60 days) | Golden, 41 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.131 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Mar 2025 | EUR 0.0700 |
| 27 Mar 2024 | EUR 0.2500 |
| 24 Mar 2023 | EUR 0.5800 |
| 25 Mar 2022 | EUR 0.4100 |
| 26 Mar 2021 | EUR 0.1600 |
| 12 Jun 2020 | EUR 0.1400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.